Antiproliferative activity of octreotide LAR in advanced neuroendocrine tumors.

4110 Background: The antiproliferative activity of Octreotide LAR in Neuroendocrine Tumors (NETs) has been demonstrated by small retrospective studies and confirmed by a prospective phase III trial (PROMID). However, there are limited data about the duration and predictors of response. The aim of our retrospective study was to determine the time to radiological progression (TTRP) of disease and the factors that were associated with better response Methods: Overall, 254 patients with advanced NETs and positive somatostatin receptor scintigraphy were included. Radiological assessment was based on RECIST criteria. Univariate and multivariate analyses were used to identify predictive factors. Median TTRP and 95% confidence intervals were calculated using Kaplan-Meier analysis. Results: The patients’ mean age was 60.5 +/- 12.8 years. Male to female ratio was 1.1. Mean follow-up was 42 months. The location of primary was in small bowel in 204, pancreas in 22, lungs in 14, rectum in 7 and unknown in 7 patients. ...